{"id":"W3093030175","doi":"10.1016/j.cllc.2020.09.013","title":"A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; National Institutes of Health; Clovis Oncology; Exelixis; Eli Lilly and Company; AstraZeneca; Shire; F. Hoffmann-La Roche; Takeda Pharmaceuticals U.S.A.; Neos Therapeutics; Foundation for the National Institutes of Health; Spectrum Pharmaceuticals; Novartis; National Cancer Institute; AbbVie; Merck; University of Colorado; Boehringer Ingelheim","keywords":"Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Oncology; Lung; Gastroenterology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001048728,0.001371518,0.001657129,0.0003559413,0.0003643753,0.000970269,0.0008670412,0.001307572,0.006169434],"category_scores_gemma":[0.0007193773,0.0005975913,0.001538,0.0002955341,0.0007654881,0.0008117352,0.0002924365,0.003579173,0.001646573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009596592,"about_ca_system_score_gemma":0.001313614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001769096,"about_ca_topic_score_gemma":0.006003695,"domain_scores_codex":[0.9997376,0.0001090416,0.000007962482,0.00005383682,0.00001956029,0.00007200138],"domain_scores_gemma":[0.9995851,0.00007117482,0.00005853179,0.00003152108,0.0000274545,0.0002262809],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7743815,0.04281417,0.004764792,0.001218681,0.00278528,0.0002267175,0.0003422428,0.002947106,0.0457548,0.0007798292,0.01422511,0.1097599],"study_design_scores_gemma":[0.8398558,0.1452366,0.007166553,0.00004468597,0.0006258691,0.0001861763,0.00007775962,0.001277505,0.001551662,0.0003303638,0.003617606,0.00002953833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814926,0.003408761,0.001243823,0.001456628,0.0004661982,0.003181642,0.003387076,0.0002274874,0.005135858],"genre_scores_gemma":[0.977737,0.002874555,0.002177211,0.001848924,0.0002351471,0.002986232,0.00517297,0.00006530995,0.006902663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006169434,"threshold_uncertainty_score":0.02063882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03232496123790799,"score_gpt":0.4204253364912456,"score_spread":0.3881003752533376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}